Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microbot MedicalFRA:CY9D +0.33%36 Buyback Yield % is -50.88 as of Jul. 26, 2026. GuruFocus rates FRA:CY9D with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 349 Medical Devices & Instruments companies, Microbot Medical ranks worse than 88.83% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Microbot Medical's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CY9D vs STXS, POCI, DXR: Buyback Yield % Comparison
For the Medical Instruments & Supplies subindustry, Microbot Medical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbot Medical Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Microbot Medical's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Microbot Medical (FRA:CY9D) has a Buyback Yield % of -50.88 as of Jul. 26, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Microbot Medical and its competitors. According to the industry distribution chart, Microbot Medical ranks #310 out of 349 companies in the Medical Devices & Instruments industry, placing it in the top 88.8%.
Is Microbot Medical's Buyback Yield % too high?
Microbot Medical's current Buyback Yield % is -50.88. Based on the distribution chart, Microbot Medical ranks #310 out of 349 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Microbot Medical has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Microbot Medical's Buyback Yield % compare to STXS and POCI?
According to the Medical Devices & Instruments industry distribution chart, Microbot Medical ranks #310 out of 349 companies for Buyback Yield %. This places Microbot Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Microbot Medical and its competitors. Microbot Medical's current Buyback Yield % is -50.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbot Medical stock overvalued right now?
Microbot Medical (FRA:CY9D) has a current Buyback Yield % of -50.88. The current Buyback Yield % is -50.88. Microbot Medical's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Microbot Medical (FRA:CY9D), the current Buyback Yield % is -50.88 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
36GF Score
Get the complete analysis for FRA:CY9D
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CY9D has been successfully added to your 
